BioCryst Historical Cash Flow
| BCRX Stock | USD 7.60 0.11 1.47% |
Analysis of BioCryst Pharmaceuticals cash flow over time is an excellent tool to project BioCryst Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 5.1 M or Depreciation of 970.6 K as it is a great indicator of BioCryst Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining BioCryst Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioCryst Pharmaceuticals is a good buy for the upcoming year.
BioCryst |
About BioCryst Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in BioCryst balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which BioCryst's non-liquid assets can be easily converted into cash.
BioCryst Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by BioCryst Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of BioCryst Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in BioCryst Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of BioCryst Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from BioCryst Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Begin Period Cash Flow is fairly stable compared to the past year. Other Non Cash Items is likely to rise to about 111.9 M in 2024, despite the fact that Change In Cash is likely to grow to (184.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 54.2M | 98.1M | 106.5M | 111.9M | Depreciation | 777K | 1.4M | 1.7M | 970.6K |
BioCryst Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
BioCryst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioCryst Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 87.4M | 158.6M | 233.4M | (201.5M) | (193.8M) | (184.1M) | |
| Free Cash Flow | (89.9M) | (137.7M) | (144.5M) | (163.2M) | (97.3M) | (92.4M) | |
| Change In Working Capital | (872K) | 26.9M | 8.1M | (58.9M) | (32.4M) | (30.8M) | |
| Begin Period Cash Flow | 28.3M | 115.7M | 274.3M | 507.7M | 306.2M | 321.6M | |
| Other Cashflows From Financing Activities | 60.1M | 142.0M | 15.7M | 14.8M | 5.3M | 5.1M | |
| Depreciation | 724K | 748K | 777K | 1.4M | 1.7M | 970.6K | |
| Other Non Cash Items | 1.3M | 2.4M | 54.2M | 98.1M | 106.5M | 111.9M | |
| Capital Expenditures | 343K | 514K | 2.4M | 1.4M | 2.2M | 2.1M | |
| Total Cash From Operating Activities | (89.6M) | (137.2M) | (142.2M) | (161.9M) | (95.1M) | (90.4M) | |
| Net Income | (108.9M) | (182.8M) | (184.1M) | (247.1M) | (226.5M) | (215.2M) | |
| Total Cash From Financing Activities | 99.1M | 302.7M | 359.7M | 88.0M | 32.5M | 57.9M | |
| End Period Cash Flow | 115.7M | 274.3M | 507.7M | 306.2M | 112.4M | 66.1M | |
| Stock Based Compensation | 17.7M | 14.8M | 34.6M | 44.7M | 55.6M | 52.8M | |
| Total Cashflows From Investing Activities | 77.9M | (6.9M) | 15.8M | (128.2M) | (115.4M) | (109.6M) | |
| Change To Liabilities | 14.8M | 24.1M | 40.7M | (22.5M) | (25.8M) | (24.5M) | |
| Change To Account Receivables | (16.2M) | 18.5M | (23.8M) | (21.5M) | (6.1M) | (6.4M) | |
| Sale Purchase Of Stock | 56.3M | 79.6M | 110.5M | 65.8M | 75.7M | 51.5M | |
| Change To Inventory | 1.6M | (7.0M) | (8.8M) | (12.4M) | (1.5M) | (1.5M) | |
| Investments | 78.3M | (6.3M) | 18.2M | (128.2M) | (25.8M) | (24.5M) | |
| Change Receivables | 1.8M | (17.9M) | 13.9M | (20.8M) | (18.7M) | (17.8M) | |
| Cash And Cash Equivalents Changes | (25.3M) | 87.4M | 158.6M | 233.4M | 268.4M | 281.8M | |
| Cash Flows Other Operating | (7.8M) | 652K | (4.0M) | 48.3M | 55.6M | 58.4M | |
| Change To Netincome | 18.1M | 15.4M | 33.0M | 141.8M | 163.1M | 171.3M | |
| Net Borrowings | 19.5M | 67.4M | 293.9M | 73.1M | 84.0M | 64.6M | |
| Change To Operating Activities | 1.7M | 4.6M | (3.0M) | (2.6M) | (2.3M) | (2.2M) | |
| Issuance Of Capital Stock | 58.5M | 93.3M | 50M | 190K | 342K | 324.9K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.